Phathom Pharmaceuticals reported a quarterly loss of $0.18 per share, slightly worse than the Zacks Consensus Estimate for a $0.17 loss. However, the result was a sharp improvement from a $1.07 loss per share a year ago, indicating materially better year-over-year earnings performance. The report is likely modestly relevant for the stock but does not include revenue or guidance details.
Phathom Pharmaceuticals reported a quarterly loss of $0.18 per share, slightly worse than the Zacks Consensus Estimate for a $0.17 loss. However, the result was a sharp improvement from a $1.07 loss per share a year ago, indicating materially better year-over-year earnings performance. The report is likely modestly relevant for the stock but does not include revenue or guidance details.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mixed
Sentiment Score
-0.10
Ticker Sentiment
